Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02979340
Other study ID # CFLD-MRE
Secondary ID U01DK062456
Status Completed
Phase
First received
Last updated
Start date January 27, 2017
Est. completion date December 27, 2019

Study information

Verified date October 2023
Source National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Specific Aim 1. Determine if valid results of non-sedated MRI based assessments of liver stiffness and lipid content can be obtained in more than 90% of children and young adults with cystic fibrosis. Specific Aim 2. Determine hepatic lipid content using the HepaFat sequence and liver stiffness using MRE. Investigators will compare the results obtained by MRI with PUSH study grayscale ultrasounds in CF patients with normal, heterogeneous, homogeneous or nodular (cirrhotic) pattern on ultrasound. Specific Aim 3. Creation of an imaging core lab to centralize evaluation of MR imaging data, allow for remote image upload, electronic data storage, and remote image viewing/interpretation. This infrastructure will be utilized to standardize image post processing. Specific Aim 4. Using the longitudinal PUSH study, determine if MRI based imaging improves discrimination of subjects at risk for progression to advanced CF liver disease (development of cirrhosis) compared to using US imaging alone


Description:

This proposal will be a cross sectional study of the current well-characterized PUSH cohort. Patients will receive an MRI at the time of their scheduled PUSH ultrasound. Ideally, the MRI will be performed the same day or a similar time point near liver ultrasound (+/-90 days, but Investigators will allow a larger window due to the slow progression of fibrosis). Blinded radiology review of imaging sequences will be performed by a local study radiologist with central review performed by the Imaging Core. Analysis by the Imaging Core will include calculation of the liver stiffness, liver and spleen volume, and hepatic and lipid content for all MRI studies.


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date December 27, 2019
Est. primary completion date December 27, 2019
Accepts healthy volunteers No
Gender All
Age group 6 Years to 26 Years
Eligibility Inclusion Criteria: 1. Currently enrolled in longitudinal follow up in PUSH study at a site with MR elastography. Exclusion Criteria: 1. Age under 6 years (all current patients at time of opening of this study will be greater than 6 years of age). 2. Internal appliance or hardware that is not compatible with MR. 3. Inability to obtain MRI within 6 months of US. 4. Inability to cooperate with MRI.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
MRI
non-invasive assessment of hepatic fibrosis and steatosis

Locations

Country Name City State
United States Children's Healthcare of Atlanta Atlanta Georgia
United States Children's Hospital Colorado Aurora Colorado
United States Johns Hopkins School of Medicine Baltimore Maryland
United States Cincinnati Children's Hospital Medical Cincinnati Ohio
United States Texas Children's Hospital Houston Texas
United States Riley Hospital for Children Indianapolis Indiana
United States Washington University School of Medicine Saint Louis Missouri
United States Seattle Children's Hospital Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Cystic Fibrosis Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change over Time in Liver stiffness and Lipid content over time using MRE Analysis of variance (ANOVA) will be used to compare the distribution of liver stiffness (in kPa) and lipid content measures between all groups defined by PUSH study grayscale ultrasounds results over time. BSL, Year 1, Year 2
See also
  Status Clinical Trial Phase
Recruiting NCT03279653 - Pancreatic Exocrine Insufficiency After Bariatric Surgery N/A
Completed NCT00763412 - Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis N/A
Recruiting NCT01851694 - Beta-cell Response to Incretin Hormones in Cystic Fibrosis N/A
Completed NCT01710644 - Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Phase 1/Phase 2
Completed NCT01988350 - Pancreatic Insufficiency Secondary to Tobacco Exposure N/A
Active, not recruiting NCT01012908 - Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Phase 2/Phase 3
Completed NCT01879228 - Effect of Chronic Incretin-based Therapy in Cystic Fibrosis N/A
Completed NCT00705978 - Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis Phase 3
Completed NCT00095732 - Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Phase 2
Completed NCT00513682 - Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Phase 3
Recruiting NCT05466838 - PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial N/A
Completed NCT00406536 - Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI Phase 2
Completed NCT00432861 - Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis Phase 3
Completed NCT01144507 - Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Completed NCT05700604 - Hypoglycemia and Glucagon Response in CF
Terminated NCT02985801 - PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer Phase 1/Phase 2
Completed NCT03551691 - Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Phase 2
Recruiting NCT03450772 - Equivalence Study to Compare Two Strengths of Creon in China Phase 3
Completed NCT00572975 - Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Phase 4
Completed NCT00880100 - Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) Phase 3